So in honor of every spell gone wrong, every mysterious bubbling flask, and every suspicious stew Snape definitely judged you ...

Beam Therapeutics (NASDAQ:BEAM) gains FDA orphan drug status for BEAM-101 to treat sickle cell disease. Read more here.

Vanqua Bio, a clinical-stage biopharmaceutical company, announced that the company will present interim Phase 1 data for its ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, ...

Transposon said its oral small molecule TPN-101 has been selected for testing as part of the HEALEY ALS platform trial.

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

The wildlife crossing will allow animals to cross over one of the busiest roadways in the world that sees around 300,000 ...

From Maine to Florida, the endangered, prehistoric fish is rebounding, but a recent study shows just how vulnerable the U.S.

Geneticists have used a cutting-edge DNA base editing treatment on several patients to cure thalassemia, a prevalent and ...

Genetic diversity enhances survival by promoting adaptation and resilience. Embracing biological and social differences is ...